Director Declaration

Summary by AI ^BETAClose X

Croda International Plc announced the appointment of Jill Anderson as a Non-Executive Director, effective January 12, 2026, who will also serve on the Audit, Nomination, and Remuneration Committees. Anderson brings over 30 years of international healthcare industry experience, including her recent role as Chief Financial Officer of GSK's R&D division until her retirement in 2024, and currently sits as a Non-Executive Director and Audit Committee Chair at Spire Healthcare Group plc. This appointment is not expected to trigger any further disclosures under LR9.6.13R of the Listing Rules.

Disclaimer*

Croda International PLC

09 January 2026

9 January 2026

Croda International Plc

The Board of Croda International Plc is pleased to announce the appointment of Jill Anderson as a Non-Executive Director. Jill will join the Board on 12 January 2026 and become a member of the Audit, Nomination and Remuneration Committees.

Jill brings more than 30 years' experience in international leadership positions in the healthcare industry, including executive responsibility in finance, commercial research and supply chain functions. Most recently, Jill was Chief Financial Officer of GSK's R&D division until she retired in 2024.

Jill is currently a Non-Executive Director and Audit Committee Chair at Spire Healthcare Group plc.

Danuta Gray, Chair of Croda International Plc, commented:

"I am delighted to welcome Jill to the Croda Board. Jill's healthcare sector experience, combined with her deep financial knowledge and her recent role as a serving Executive make her an excellent addition to the Board."

Jill Anderson commented:

"I feel very privileged to be joining Croda, especially given the strong purpose and commitment to use innovation with Smart science to improve lives^TM. Croda has an exciting future, and I look forward to working as part of the Croda team."

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Media: Charlie Armitstead, FTI Consulting +44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END